---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Psychotherapy"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Psychotherapy. Topics: CANMAT guideline: psychotherapy after poor response to an initial antidepressant, NICE guideline: psychological therapy after no or limited response to medication, VA/DoD guideline: switching to or augmenting with psychotherapy, VA/DoD guideline: patient burden and access to psychotherapy, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/psychotherapy"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Psychotherapy

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Psychotherapy

<a id="topic-2.2.2.1.4-1"></a>

### CANMAT guideline: psychotherapy after poor response to an initial antidepressant

> “Based on efficacy and low potential for side effects, first-line psychological treatments should be considered early in the treatment course”
> “There are few studies of psychotherapy for patients showing poor response to antidepressants.”
> “Hence, CBT is recommended as a second-line adjunctive treatment, with medications, for DTD.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.4-2"></a>

### NICE guideline: psychological therapy after no or limited response to medication

> “switching to a psychological therapy (see the section on suggested treatment options for more severe depression)”
> “changing to a combination of psychological therapy (for example, CBT, interpersonal psychotherapy [IPT] or STPP) and medication.”
> “If a person's depression has had no or a limited response to treatment with a combination of antidepressant medication and psychological therapy, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences.”
> “switching to another psychological therapy”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.4-3"></a>

### VA/DoD guideline: switching to or augmenting with psychotherapy

> “Switching to psychotherapy”
> “Augmenting with a psychotherapy”
> “Combined pharmacotherapy and psychotherapy are options if a response or remission is not achieved with an antidepressant as initial monotherapy.”
> “In an SR by Li et al. (2018) where the comparators were TAU (three RCTs), psychoeducation (one RCT), health enhancement program (one RCT), and medication change (one RCT), which included participants who were receiving pharmacotherapy at baseline, the addition of psychotherapy (i.e., CBT) resulted in improvement in symptoms of depression and remission.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.4-4"></a>

### VA/DoD guideline: patient burden and access to psychotherapy

> “However, psychotherapy can be burdensome due to a required time commitment and frequent visits. Further, there may be limited access to recommended evidence-based psychotherapies since not all providers have adequate training in them.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.4-5"></a>

### ACP guideline: switching to or augmenting with cognitive behavioral therapy

> “ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence)”

Source: [Qaseem et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36689752/)

<a id="topic-2.2.2.1.4-6"></a>

### Cognitive behavioral therapy added to usual care in primary care: response at 6 months

> “This two parallel-group multicentre randomised controlled trial recruited 469 patients aged 18-75 years with treatment resistant depression (on antidepressants for ≥6 weeks, Beck depression inventory [BDI] score ≥14 and international classification of diseases [ICD]-10 criteria for depression) from 73 UK general practices.”
> “The primary outcome was response, defined as at least 50% reduction in depressive symptoms (BDI score) at 6 months compared with baseline.”
> “95 participants (46%) in the intervention group met criteria for response at 6 months compared with 46 (22%) in the usual care group (odds ratio 3·26, 95% CI 2·10-5·06, p<0·001).”
> “Because of the nature of the intervention it was not possible to mask participants, general practitioners, CBT therapists, or researchers to the treatment allocation.”

Source: [Wiles et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219570/)

<a id="topic-2.2.2.1.4-7"></a>

### Cognitive behavioral therapy added to usual care: long-term follow-up and cost-effectiveness

> “Of these, 248 individuals completed a long-term follow-up questionnaire and provided data for the primary outcome (136 in the intervention group vs 112 in the usual care group). At follow-up (median 45·5 months [IQR 42·5-51·1]), the intervention group had a mean BDI-II score of 19·2 (SD 13·8) compared with a mean BDI-II score of 23·4 (SD 13·2) for the usual care group (repeated measures analysis over the 46 months: difference in means -4·7 [95% CI -6·4 to -3·0, p<0·001]).”
> “The average annual cost of trial CBT per participant was £343 (SD 129). The incremental cost-effectiveness ratio was £5374 per QALY gain.”

Source: [Wiles et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26777773/)

<a id="topic-2.2.2.1.4-8"></a>

### Psychological therapies for treatment-resistant depression: Cochrane review

> “We included six trials (n = 698; most participants were women approximately 40 years of age). All studies evaluated psychotherapy plus usual care (with antidepressants) versus usual care (with antidepressants).”
> “Moderate‐quality evidence for remission from six studies (RR 1.92, 95% CI 1.46 to 2.52; n = 635) and low‐quality evidence for response from four studies (RR 1.80, 95% CI 1.2 to 2.7; n = 556) indicate that psychotherapy was beneficial as an adjunct to usual care over the short term.”
> “High‐quality evidence shows no differential dropout (a measure of acceptability) between intervention and comparator groups over the short term (RR 0.85, 95% CI 0.58 to 1.24; six studies; n = 698).”
> “No evidence currently shows whether switching to a psychotherapy is more beneficial for this patient group than continuing an antidepressant medication regimen.”

Source: [Ijaz et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6494651/)

<a id="topic-2.2.2.1.4-9"></a>

### Psychotherapy for treatment-resistant depression: meta-analysis and meta-regression

> “Seven different psychotherapies were studied in 21 trials that included a total of 25 comparisons. In three comparisons of psychotherapy v. treatment as usual (TAU) we found no evidence to conclude that there is a significant benefit of psychotherapy as compared with TAU. In 22 comparisons of add-on psychotherapy plus TAU v. TAU only, we found a moderate general effect size of 0.42 (95% CI 0.29-0.54) in favor of psychotherapy plus TAU.”
> “Most frequent investigated treatments were cognitive behavior therapy, interpersonal psychotherapy, mindfulness-based cognitive therapy, and cognitive behavioral analysis system of psychotherapy.”

Source: [van Bronswijk et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30139408/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
